Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202728 | 0.85 | GFER (0.45) | KDM4EGAAMAPTALDH1A1PDE2A | |
| SCHEMBL20160541 | 0.83 | TNKS (0.45) | KDM4ETDP1MC4RGAALMNA | |
| SCHEMBL13923299 | 0.79 | MC4R (0.52) | KDM4EMC4RGAALMNAMAPT | |
| SCHEMBL24135434 | 0.78 | ALDH1A1 (0.45) | TDP1LMNAALDH1A1PTPN1 | |
| SCHEMBL6555500 | 0.78 | NPC1 (0.47) | KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2933048 | 0.77 | KDM4E (0.45) | KDM4ETDP1MC4RGAALMNA | |
| SCHEMBL27360423 | 0.77 | MC4R (0.46) | KDM4ETDP1MC4RGAALMNA | |
| SCHEMBL20322780 | 0.76 | HDAC6 (0.43) | KDM4EMC4RLMNAMAPTALDH1A1 | |
| SCHEMBL1252213 | 0.74 | GAA (0.48) | KDM4ETDP1MC4RGAALMNA | |
| SCHEMBL20160565 | 0.74 | TNKS (0.41) | KDM4ETDP1MC4RGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-12162879-B2 | Pyridopyrimidine derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2024-12-10 | — | — | US | disclosed |
| CN-115710266-B | Pyridopyrimidine derivative, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-115028637-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| CN-115710266-A | Pyridopyrimidine derivative, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-4134368-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-15 | — | — | EP | disclosed |
| CN-113082224-A | Pyridopyrimidine derivative conjugate, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-3822271-A1 | PYRIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-25 | — | — | US | disclosed |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3790879-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-03-17 | — | — | EP | disclosed |
| CN-112469721-A | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-111094289-A | Pyridopyrimidine derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2020007275-A1 | PYRIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2020-01-09 | — | — | WO | disclosed |
| WO-2019215316-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215316-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | KDM4E 1071/4885TDP1 818/4885MC4R 552/4885 |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | KDM4E 1071/4885TDP1 818/4885MC4R 552/4885 |
| US-12162879-B2 | Pyridopyrimidine derivative, preparation method therefor and medical use thereof | TLR8, TLR7, TLR1 | KDM4E 3762/4885TDP1 1731/4885MC4R 554/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | KDM4E 1071/4885TDP1 818/4885MC4R 552/4885 |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | KDM4E 1071/4885TDP1 818/4885MC4R 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.